Development of a cobalt(iii)-based ponatinib prodrug system

Receptor tyrosine kinase inhibitors have become a central part of modern targeted cancer therapy. However, their curative potential is distinctly limited by both rapid resistance development and severe adverse effects. Consequently, tumor-specific drug activation based on prodrug designs, exploiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathuber, Marlene, Gutmann, Michael, La Franca, Mery, Vician, Petra, Laemmerer, Anna, Moser, Patrick, Keppler, Bernhard K., Berger, Walter, Kowol, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129988/
https://www.ncbi.nlm.nih.gov/pubmed/34046181
http://dx.doi.org/10.1039/d1qi00211b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129988/
https://www.ncbi.nlm.nih.gov/pubmed/34046181
http://dx.doi.org/10.1039/d1qi00211b

Ejemplares similares